期刊文献+

Detection of gemcitabine-resistant genes expression in lung cancer cell lines using real-time PCR

实时荧光PCR法检测肺癌细胞系中吉西他滨耐药相关基因的表达(英文)
下载PDF
导出
摘要 Objective: To explore the molecular mechanism of gemcitabine-resistance, the relative mRNA expression of five genes related to gemcitabine-resistance was detected in six lung cancer cell lines. Methods: The total RNA was extracted from six lung cancer cell lines GLC-82, NCI-H460, A549, 95-C, 95-D and QG56. Then the cDNA was amplified by real-time quantitative PCR method to quantify the gene expression of RRM1, PTEN, ERCC1, dCK and CDA. The cytotoxicity of gem- citabine to cell lines was tested by MTT method. Results: Among the detected six lung cancer cell lines, the mRNA level of RRM1, PTEN and ERCC1 in lung squamous cell line QG56 was highest, and the IC50 of gemcitabine to QG56 cell line was also highest. Conclusion: The mRNA expression of RRM1, PTEN and ERCC1 was correlated, and the high expression of RRM1 was related to gemcitabine resistance of lung cancer.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2008年第12期682-685,共4页 中德临床肿瘤学杂志(英文版)
基金 Supported by a grant from the Capital Medical Developing Foundation of China (No. 03028)
关键词 gemcitabine-resistant real-time PCR gene expression lung cancer 肺癌 治疗 临床 基因 抵抗能力
  • 相关文献

参考文献9

  • 1Rosell R, Crino L, Danenberg K, et al. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol, 2003, 30: 19-25.
  • 2Sarries C, Haura EB, Roig B, et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics, 2002, 3: 763-780.
  • 3Pitterle DM, Kim YC, Jolicoeur EM, et al. Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm Genome, 1999, 10: 916-922.
  • 4Bepler G, Zheng Z, Gautam A, et al. Ribonucleotide reductase M1 gene promoter activity polymorphisms, population frequencies and clinical relevance. Lung cancer, 2005, 47: 183-192.
  • 5Rosell R, Danenberg KD, Alberola V, et al.Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatintreated advanced non-small cell lung cancer patients. Clin Cancer Res, 2004, 10: 1318-1325.
  • 6Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non- small cell lung cancer. J Clin Oncol, 2004, 22: 1878-1885.
  • 7Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res, 2004, 64: 3761-3766.
  • 8Rosell R, Taron M, Barnadas A, et al. Nucleotide excision repair pathways involved in cisplatin resistance in non-small cell lung cancer. Cancer Control, 2003, 10: 297-305.
  • 9Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross- complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinumbased chemotherapy. Clin Cancer Res, 2004, 10: 4939-4943.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部